BioDuro

34 articles about BioDuro

• BioDuro-Sundia and X-Chem Enter Partnership to Launch DEL Services in China for the Discovery of New Small Molecule Drugs

  8/8/2022

  BioDuro-Sundia, an industry-leading drug discovery, development and commercial service CRDMO backed by Advent International, and X-Chem, a DEL technology pioneer in small molecule drug discovery, jointly announced the launch of DNA Encoded Compound Library technology services in China to help more innovative pharmaceutical companies quickly discover small molecule drugs.

• BioDuro-Sundia Completes First GMP Drug Product Manufacturing at New China Site

  4/13/2021

  Team scores perfect quality record, initiating production facility with capacity of 60 million oral dosage form units

• BioDuro and Sundia Partner as an Industry Leading Contract Research, Development and Manufacturing Organization

  9/25/2020

  BioDuro, a global life science research and development organization backed by Advent International (“Advent”), and Sundia, a leading contract research and manufacturing organization, today announced that they have partnered to create one of the largest CRDMOs (contract rese

• BioDuro & neoX Partner to Create Next Generation Antibody Discovery Platform

  4/28/2020

  Companies Combine Leading-edge AI Antibody Evolution & Advanced Synthetic Antibody Screening --

• BioDuro Strengthens Senior Leadership of Global CMC Solutions Business Unit

  4/1/2020

  BioDuro, LLC, announced today the appointment of two senior leadership positions to the Global CMC Solutions business unit: Firouz Asgarzadeh, PhD as Vice President of Pharmaceutics and Mindy Weir as Executive Director Quality. “BioDuro is

• BioDuro Launches New Antibody & Cell Therapy Discovery Services

  3/2/2020

  BioDuro LLC, a leading global life sciences contract research and development organization, announced today that it has broadly launched new antibody- and cell-based therapy discovery services.

• BioDuro Welcomes New President, Global CMC Solutions

  12/6/2019

  BioDuro, LLC, a leading global life sciences contract research, development and manufacturing services organization, is pleased to announce the appointment of Kent Payne, Ph.D., as President of its CMC Global Solutions business unit.

• BioDuro chooses SciFinder-n from CAS to enhance research productivity and shorten cycle times for client success

  11/18/2019

  Collaboration between drug companies and contract research partners drives innovation in evolving business environment

• BioDuro Welcomes New Chief Financial Officer

  11/5/2019

  BioDuro, LLC, a leading global life sciences contract research, development and manufacturing services organization, announced today the appointment of Jeffery Blazevich as the new Chief Financial Officer.

• BioDuro Announces New Leadership Positions for Continued Expansion

  5/1/2019

  BioDuro, LLC, a leading drug discovery and development services organization, announced today the appointment of four senior leadership positions, including David Hedden, Ph.D. (Chief Scientific Officer), Brett Truitt, MS, MBA (Vice President, cGMP Operations), Mohan Thiruvazhi, Ph.D. (Vice President, Business Development), and Raymond Li, CPA, MBA (Vice President, Finance).

• BioDuro partners with Advent International

  1/28/2019

  Advent's strategic investment will strengthen BioDuro's leadership position as a trusted global provider of drug discovery and development services   [27-January-2019]   SAN DIEGO , BEIJING and SHANGHAI , Jan. 27, 2019 /PRNewswire/ -- BioDuro, a leading global life sciences contract research and development organization, and Advent International, one of the largest and m

• MilliporeSigma Signs Exclusive OEM Agreement with BioDuro, LLC

  12/4/2018

  AISF was developed through a research collaboration with Pfizer Inc.

• BioDuro Launches New Drug Discovery Site in San Diego, CA

  10/9/2018

  Suite of chemistry and biology capabilities help drug developers advance into the clinic with confidence

• BioDuro Collaboration with Pfizer Inc. Leads to Creation of a Shelf-Stable Fluorosulfation Reagent

  3/19/2018

  New reagent serves as a stable, solid alternative to toxic sulfuryl fluoride gas.

• BioDuro Completes Acquisition of Molecular Response to Accelerate Translational Oncology Capabilities

  3/5/2018

  Company adds 100,000 tumors to portfolio; enables broad access to proven technology platform.

• BioDuro Announces Cooperation Agreement With Porton Pharma Solutions

  1/30/2018

  Under this agreement, BioDuro will promote and market Porton's extensive and proven capabilities for pilot and large-scale GMP production of custom APIs and drug intermediates.

• BioDuro, LLC Launches Humanized Tumor Microenvironment, Three-Dimensional Drug Screening And Patient-Derived Xenograft Verification Platform: hTME-3DX Screen And Verify

  3/29/2017

• BioDuro, LLC Increases Spray Dried Drug Product Manufacturing Capacity

  11/9/2016

• BioDuro, LLC Completes Infrastructure Expansion In Shanghai To Accommodate 130 Additional Chemistry And Biology Staff For Its Integrated Drug Discovery And Development Programs And To Enable Rapid Scale Up For Process-Chemistry

  9/6/2016

• BioDuro, LLC Launches As Unique Contract Research And Drug Manufacturing Organization

  6/7/2016